At the cellular level, the exposure of BRAF-mutant melanoma cells to the compound resulted in a marked down-modulation of KIT, which was paralleled by the shutdown of the MAPK and PI3K/AKT signaling pathways, both at the transcriptomic and post-translational levels. The gene discussed is KIT; the disease is melanoma.